Lipgloss and Aftershave

NOVEMBER 1, 2024

Jenni Nagle, L+A CO-Founder had a CO2 laser treatment and kept an eight day diary of her recovery process! For estheticians and skincare professionals, addressing pigmentation involves understanding and applying a multimodality treatment approach, which combines various techniques to tackle pigmentation through multiple mechanisms.

Chemical Peels 52

Chemical Peels Hyperpigmentation Vitamin C Microneedling 52

AAAMS

JANUARY 21, 2025

Why AAAM Certification is Essential for Your Medspa Starting a med spa involves more than setting up a luxurious facilityit requires a solid foundation of expertise in aesthetic procedures to provide safe, effective treatments. It combines convenience with comprehensive instruction and is ideal for busy professionals.

Med Spa 52

Med Spa Chemical Peels Training Legal 52

The Dermatology Digest

FEBRUARY 20, 2025

VYN202 is an oral small molecule BD2-selective bromodomain and extra-terminal domain (BET) inhibitor that is being developed for the treatment of immune-mediated diseases. Following the 12-week treatment period, all subjects will be followed for a 4-week safety period.

Safety 36

Safety Office Dermatology Treatments 36

The Dermatology Digest

APRIL 11, 2025

anhydrous gel is showing promise in the treatment of microcystic lymphatic malformations (microcystic LMs), according to a presentation at the 15th World Congress of Pediatric Dermatology in Buenos Aires, Argentina. million from FDAs Office of Orphan Products Development. Palvella Therapeutics, Inc. s QTORIN rapamycin 3.9%

Therapy 36

Therapy Dermatology Office Clinic 36

Natural Beauty Med Spa

JANUARY 4, 2025

When you think of carbon dioxide, beauty treatments might be among the last things that come to mind. But did you know that CO2 can actually provide amazing results as part of a skincare treatment? Lets talk about why you can be confident in the safety of this treatment. Do CO2Lift Treatments Have Side Effects?

Med Spa 52

Med Spa Treatments Chemical Peels Skin Types 52

The Dermatology Digest

MARCH 17, 2025

The overall safety profile of povorcitinib is consistent with previous data. No new safety signals were observed and both doses were well tolerated. “The positive Phase 3 data highlights the potential of povorcitinib as an effective oral treatment option for people living with HS.

Safety 36

Safety Document Clinic Therapy 36

The Dermatology Digest

JUNE 5, 2024

Top-line data from the 24-week vehicle-controlled treatment period are expected in mid-2025. Check out TDD’s one-on-one interview with Iain Stuart, PhD , Chief Scientific Officer at Vyne Therapeutics. VYN201 is a novel pan-bromodomain and extra-terminal domain (BET) inhibitor designed for local administration.

Safety 73

Safety Office Facials Therapy 73

The Dermatology Digest

JANUARY 22, 2025

The Companies intend to first evaluate Xyngari with for the topical treatment of primary axillary hyperhidrosis and may explore additional indications through a broader partnership in the future. Dermata Therapeutics, Inc. and Revance Therapeutics, Inc.

Injections 36

Injections Office Partnerships Clinic 36

The Dermatology Digest

NOVEMBER 6, 2024

This award was established this year to accelerate the translation of research into potential treatments and diagnostics for lupus. He will test ONT01, which has shown promising results in mouse models, in a phase 1b trial to assess its safety in people with lupus.

Hospital 36

Hospital Therapy Management Networking 36

The Dermatology Digest

MARCH 18, 2024

Food and Drug Administration (FDA) has accepted Journey Medical’s New Drug Application (NDA) for DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the treatment of inflammatory lesions and erythema of rosacea in adults. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of November 4, 2024. “We

Rosacea 74

Rosacea Medical Office Clinic 74

The Dermatology Digest

JANUARY 20, 2024

By blocking MRGPRX2 activation and degranulation of mast cells, EVO756 has the potential to be a first-in-class oral treatment for a variety of mast cell-mediated diseases, including chronic spontaneous urticaria and inflammatory itch. Evommune, Inc.

Safety 74

Safety Office Dermatitis Clinic 74

The Dermatology Digest

JANUARY 29, 2024

Food and Drug Administration (FDA) for treatment of seborrheic dermatitis in adult and pediatric patients 9 years of age and older in December 2023. Zoryve foam was well-tolerated with a favorable safety and tolerability profile. There were no treatment-related Serious Adverse Events (SAEs). Zoryve foam was approved by the U.S.

Dermatitis 74

Dermatitis Safety Dermatology Treatments 74

The Dermatology Digest

FEBRUARY 10, 2025

In patients with moderate-to-severe AD, rezpegaldesleukin has been shown to rapidly improve measurable exploratory disease outcomes during a 12-week induction treatment phase and for at least 36 weeks after ceasing treatment, demonstrating proof-of-concept in this indication.

Dermatitis 36

Dermatitis Therapy Office Safety 36

The Dermatology Digest

SEPTEMBER 20, 2024

s Investigational Device Exemption (IDE) application to initiate a multi-center study for the treatment of recurrent cutaneous Squamous Cell Carcinoma (cSCC) in immunocompromised patients using Diffusing Alpha-emitters Radiation Therapy (Alpha DaRT). Food and Drug Administration (FDA) has approved Alpha Tau Medical Ltd.’s Dr. Robert B.

Office 74

Office Clinic Safety Medical 74

The Dermatology Digest

FEBRUARY 14, 2024

VTAMA cream, 1% is currently approved for the topical treatment of plaque psoriasis in adults in the U.S. VTAMA cream, 1% data indicated no new safety or tolerability signals of concern in this population including children 2 years of age and older.

Dermatitis 74

Dermatitis Office Management Eczema 74

The Dermatology Digest

FEBRUARY 11, 2025

is restructuring to focus on the advancement of its bempikibart clinical development program for the treatment of patients with alopecia areata (AA). “We have conviction that bempikibart is differentiated from existing AA therapies and has the potential to transform the treatment paradigm for this disease. Q32 Bio Inc.

Clinic 36

Clinic Therapy Office Tools 36

The Dermatology Digest

JANUARY 14, 2024

The PDE4 inhibitor is the first topical treatment for seborrheic dermatitis with a new mechanism of action in more than 20 years. Zoryve foam was well-tolerated with a favorable safety and tolerability profile. There were no treatment-related Serious Adverse Events (SAEs). of the total study population).

Dermatitis 72

Dermatitis Office Dermatology Safety 72

The Dermatology Digest

MAY 16, 2024

Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami, Miller School of Medicine, adds: “With only two FDA approved biologics, there is still an urgent need for new treatment options that treat all patient types and lesions, with the opportunity for inflammatory remission. HiSCR75 and beyond).

Safety 68

Safety Clinic Dermatology Office 68

The Dermatology Digest

JUNE 10, 2024

Food and Drug Administration (FDA) approved Almirall’s recent supplemental New Drug Application (sNDA) to expand the use area of tirbanibulin ( Klisyri) for the treatment of actinic keratosis (AK) on the face or scalp up to 100 cm 2.

Treatments 36

Treatments Safety Office Clinic 36

The Dermatology Digest

FEBRUARY 26, 2024

Sonelokimab is a novel investigational nanobody for the treatment of inflammatory disease. This represents a crucial step in offering a potential innovative treatment option to patients and their dedicated physicians, addressing a condition that is often under-recognized, under-treated and significantly impacts patients’ lives.”

Office 74

Office Clinic Innovations Safety 74

North Dallas Dermatology Associates

NOVEMBER 1, 2023

By Juliet Gibson, MD The demand for cosmetic treatments has increased rapidly, resulting in a variety of options to reverse the effects of aging. The skill of the provider, and the area, can affect both your health and the overall outcome of the treatment. This added layer of safety provides peace of mind to patients.

Office 36

Office Safety Medical Training 36

Natural Beauty Med Spa

APRIL 28, 2024

Laser skin resurfacing is a popular cosmetic treatment that has the potential to drastically improve the appearance of the skin. However, you might be reluctant to commit to it due to concerns about safety. Another factor that should be kept in mind is the professional that performs the treatment. Is it worth it?

Med Spa 52

Med Spa Scarring Safety Makeup 52

The Dermatology Digest

JULY 29, 2024

Key secondary endpoints will include PASI 90, PASI 100 and sPGA 0 measured at Weeks 16 and 24, and safety and tolerability. Patients completing Week 24 will have the opportunity to participate in a long-term extension (LTE) trial, ONWARD3, that will evaluate durability and maintenance of response and long-term safety.

Clinic 36

Clinic Safety Office Treatments 36

The Dermatology Digest

SEPTEMBER 12, 2024

In the confirmatory phase 3 study (LIBERTY-CUPID Study C), dupilumab met the primary and key secondary endpoints for the investigational treatment of patients with uncontrolled, biologic-naïve CSU receiving background therapy with antihistamines. At 24 weeks, efficacy among patients receiving Dupixent compared to placebo was as follows: 8.64-point

Safety 36

Safety Office Medical Dermatology 36

The Dermatology Digest

APRIL 9, 2025

XERFs Wave Fit pulse and Advanced Integrated Cryogen Delivery (ICD) Cooling technologies work in tandem to regulate energy delivery and maintain optimal surface temperature for comfortable treatment experience without the need for numbing. This tip ensures a controlled treatment environment, increasing treatment efficacy and patient safety.

Technology 36

Technology Office Surgery Safety 36

The Dermatology Digest

APRIL 18, 2024

Extra-strength 40U formulation of prabotulinumtoxinA-xvfs (Jeuveau, Evolus) performed well in a Phase 2 trial for the treatment of moderate to severe glabellar lines in adults. The safety profile was similar across all three arms and overall, 88.9% The safety profile was similar across all three arms and overall, 88.9%

Safety 36

Safety Office Surgery Dermatology 36

The Dermatology Digest

FEBRUARY 22, 2024

for the treatment of seborrheic keratoses. “We for the treatment of SK lesions, the most common benign tumors of the skin,” shares Karl Beutner, M.D., The primary endpoints of the study are the proportion of SK lesions with a Physician Lesion Assessment (PLA) score of clear (PLA=0) at last visit and the safety of SM-020 gel 1.0%

Safety 36

Safety Clinic Office Hyperpigmentation 36

The Dermatology Digest

FEBRUARY 22, 2024

for the treatment of seborrheic keratoses. “We for the treatment of SK lesions, the most common benign tumors of the skin,” shares Karl Beutner, M.D., The primary endpoints of the study are the proportion of SK lesions with a Physician Lesion Assessment (PLA) score of clear (PLA=0) at last visit and the safety of SM-020 gel 1.0%

Safety 36

Safety Clinic Office Hyperpigmentation 36

Fairlawn Aesthetic MD

JULY 19, 2023

It’s an innovative treatment in the field of aesthetic medicine that’s designed to help you look and feel your absolute best. The Cryo T-Shock procedure involves alternating cycles of cryo (cold) and thermo (heat) treatments applied directly to the skin. It’s a comfortable and safe treatment.

Treatments 36

Treatments Diet Consultations Consultation 36

The Dermatology Digest

JANUARY 5, 2024

s Phase 2 trial of VP-315, a potential first-in-class oncolytic peptide, for the treatment of basal cell carcinoma. The last patient has been dosed in Part 2 of Verrica Pharmaceuticals Inc.’s VP-315 is a chemotherapeutic administered intratumorally.

Pharmaceutical 36

Pharmaceutical Safety Office Clinic 36

The Dermatology Digest

JANUARY 5, 2024

Food and Drug Administration (FDA) seeking approval for DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the treatment of inflammatory lesions and erythema of rosacea in adults. The NDA submission is based on positive data from Journey Medical’s two DFD-29 Phase 3 clinical trials for the treatment of rosacea.

Rosacea 36

Rosacea Medical Office Clinic 36

The Dermatology Digest

MAY 6, 2024

The Phase 2a trial ( NCT05984784 ) evaluates the safety, pharmacokinetics, and efficacy of IMG-007 in adult patients with moderate-to-severe AD who had inadequate response to and/or intolerant of topical therapies. Key study endpoints include safety and percent change from baseline in eczema area and severity index (EASI) over time.

Safety 36

Safety Therapy Dermatitis Eczema 36

The Dermatology Digest

JANUARY 24, 2024

Delgocitinib cream demonstrated a superior reduction in Hand Eczema Severity Index (HECSI) score from baseline to Week 12 compared to alitretinoin capsules in people with severe chronic hand eczema, according to results from the DELTA FORCE Trial, which is the first head-to-head phase 3 trial comparing a systemic and topical treatment for CHE.

Eczema 36

Eczema Safety Office Treatments 36

The Dermatology Digest

AUGUST 21, 2024

The trial did not show a statistically significant difference between the proportion of patients treated with TMB-001 responding to treatment after 12 weeks compared with patients treated with vehicle. After encouraging phase 2b results, we observed an unexpectedly high vehicle response in this trial.

Pharmaceutical 36

Pharmaceutical Clinic Office Dermatology 36

Art of Dermatology

MAY 17, 2024

At Art of Dermatology at the Laser and Skin Surgery Center of New York, patient safety and satisfaction is Dr. Jessica Krant’s primary concern. Making sure you are seeing a board-certified core cosmetic specialty physician (dermatologist, plastic surgeon, oculoplastic surgeon, or ENT facial plastic surgeon) in a real medical office is key.

Office 36

Office Surgery Safety Injections 36

The Dermatology Digest

SEPTEMBER 30, 2024

s ESK-001 is a highly selective TYK2 inhibitor currently being evaluated in the Phase 3 ONWARD clinical program for the treatment of moderate-to-severe plaque psoriasis. Treatment emergent adverse event (TEAE) frequency and severity were similar across study arms, with the majority being mild-to-moderate and self-limited. Alumis Inc.’s

Clinic 36

Clinic Safety Sustainability Office 36

The Dermatology Digest

FEBRUARY 7, 2024

For the study, 255 participants were randomized into six treatment groups (placebo [n=43], 25 mg daily [n=43], 25 mg twice-daily [n=41], 50 mg daily [n=43], 100 mg daily [n=43], and 100 mg twice-daily [n=42]). Improvements were also consistent across Patient Reported Outcomes through Week 16.

Safety 36

Safety Clinic Office Dermatology 36